Osimertinib 80 MG

DRUG6 trials

Conditions

Circulating Tumor CellEGF-R Positive Non-Small Cell Lung CancerLocally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)Lung CancerLung Cancer Non-small Cell Stage IVNon Small Cell Lung CancerStage IV Non-small Cell Lung Cancer

Early Phase 1

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Not yet recruitingNCT06557096

Second Affiliated Hospital of Nanchang UniversityCirculating Tumor Cell, EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer

Start: 2024-08-20End: 2028-07-31Target: 100Updated: 2024-08-16

Phase 2

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

CompletedNCT04184921

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityLung Cancer Non-small Cell Stage IV

Start: 2019-01-01End: 2024-06-01Updated: 2026-02-03

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

RecruitingNCT04591002

Samsung Medical CenterLung Cancer

Start: 2022-07-26End: 2028-10-30Target: 43Updated: 2025-06-26

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

RecruitingNCT07058519

Shanghai Chest HospitalLocally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)

Start: 2025-09-23End: 2029-01-24Target: 250Updated: 2025-11-26

Unknown Phase

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

CompletedNCT04965701

Istituto Oncologico Veneto IRCCSEGF-R Positive Non-Small Cell Lung Cancer

Start: 2018-06-01End: 2023-05-31Updated: 2023-11-13

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

NCT05583409

Li ZhangStage IV Non-small Cell Lung Cancer

Start: 2023-01-01End: 2025-12-30Target: 72Updated: 2022-10-17

Related Papers

Osimertinib in Patients With Treatment-Naive <i>EGFR</i>-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World